BIRMINGHAM, Ala., Jan. 10 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced Thomas J. Simon, M.D. has joined BioCryst as a consultant and interim Chief Medical Officer. Dr. Simon brings more than 20 years of expertise in global pharmaceutical development to his position at BioCryst.
"We are very pleased to have Tom join BioCryst at this important time," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst. "Tom brings a sound knowledge of systematic, worldwide product development from his tenure at Merck & Co. where he was responsible for moving several key products from the clinical development-stage through to marketing approval. As our programs continue to move forward Tom's expertise in product development will be of immeasurable value."
The Company has undertaken a search to find a permanent successor to Dr. Simon.
Most recently, Dr. Simon held the position of Vice President, Clinical and Quantitative Sciences Administration at Merck & Co. with responsibility as Acting Head of Oncology Clinical Research. During his tenure with Merck & Co, Dr. Simon held various senior clinical positions including responsibility for resource allocation and shared services in Clinical and Quantitative Sciences and Vice President, Gastroenterology Clinical Research. Prior to joining Merck & Co., Dr. Simon held senior clinical positions at William H. Rorer, Inc. of Ft. Washington, Pennsylvania and also at Miles Pharmaceuticals of West Haven, Connecticut.
Dr. Simon received his B.S. and M.S. from Stanford University and his M.D. from the University of California, San Diego. He completed his fellowship in gastroenterology at the University of Colorado and received his M.B.A. from the Wharton School of Business at the University of Pennsylvania. He is the author of numerous clinical and scientific publications and has secured five patents.
Dr. James Alexander will assume the role of Vice President Clinical Development reporting to Dr. Simon.
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including forodesine HCl in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of forodesine HCl in markets across Europe, Asia, Australia and certain neighboring countries. In February 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.
This press release contains forward-looking statements, including
statements regarding future results, performance or achievements. These
statements involve known and unknown risks, uncertainties and other factors
which may cause our actual results, performance or achievements to be
materially different from any future results, performances or achievements
expressed or implied by the forward-looking statements. These statements
reflect our current views with respect to future events and are based on
assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these forward-looking
statements. Some of the factors that could affect the forward-looking
statements contained herein include that our belief that many subjects in
the Phase II clinical trials of peramivir did not receive adequate dosing
by i.m. injection may not be correct, that DHHS and the FDA may not agree
with our analysis, that DHHS may further condition, reduce or eliminate
future funding of the peramivir program, that the peramivir program may not
be successful, that the pivotal trial with forodesine HCl in CTCL may not
meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may
not be successfully completed, that development and commercialization of
forodesine HCl in CTCL may not be successful, that we or our licensees may
not be able to enroll the required number of subjects in planned clinical
trials of our product candidates and that such clinical trials may not be
successfully completed, that BioCryst or its licensees may not commence as
expected additional human clinical trials with our product candidates, that
our product candidates may not receive required regulatory clearances from
the FDA, that ongoing and future clinical trials may not have positive
results, that we may not be able to announce preclinical developments for
additional compounds by year-end 2007 as currently proposed, that we or our
licensees may not be able to continue future development of our current and
future development programs, that our development programs may never result
in future product, license or royalty payments being received by BioCryst,
that BioCryst may not reach favorable agreements with potential
pharmaceutical and biotech partners for further development of its product
candidates, that our projected burn rate may not be consistent with our
expectations, that BioCryst may not have sufficient cash to continue
funding the development, manufacturing, marketing or distribution of its
products and that additional funding, if necessary, may not be available at
all or on terms acceptable to BioCryst. Please refer to the documents
BioCryst files periodically with the Securities and Exchange Commission,
specifically BioCryst's most recent Annual Report on Form 10-K, most recent
Registration Statement on Form S-3 (File No. 333-145638), Quarterly Reports
on Form 10-Q, current reports on Form 8-K which identify important factors
that could cause the actual results to differ materially from those
contained in the projections or forward-looking statements.
BioCryst Pharmaceuticals, Inc.
Jonathan M. Nugent
V.P. Corporate Communications
|SOURCE BioCryst Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved